RecruitingNot ApplicableNCT06995664

Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management

Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management - a Randomised Feasibility Study


Sponsor

Royal Marsden NHS Foundation Trust

Enrollment

24 participants

Start Date

Mar 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Prospective, randomised, feasibility study of patients with localised or metastatic renal cell carcinoma (RCC) comparing standard palliative dose radiotherapy to a high-dose hypofractionated regime. Primary aim • To demonstrate feasibility of a randomised study comparing high-dose hypofractionated radiotherapy versus standard palliative dose radiotherapy in localised or metastatic renal cell carcinoma The aim is to recruit a minimum of 24 patients; 12 to the control arm and 12 to the high-dose regime. 2 treatment arms, no placebo: * Control arm - standard palliative-dose radiotherapy, 30Gy in 10 fractions in 3Gy per fraction over 2 weeks * High-dose arm - high-dose radiotherapy, 30Gy in 5 fractions in 6Gy per fraction on alternate days/2-3 fractions a week over 2 weeks


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests high-dose radiation therapy targeted at only part of a kidney cancer tumor — rather than the whole tumor — to see whether this can control tumor growth while preserving surrounding healthy tissue. It is intended for patients who cannot have surgery or other ablative treatments. **You may be eligible if...** - You have been diagnosed with renal cell carcinoma (kidney cancer), confirmed by biopsy or a clinical team review - Surgery, ablation, or other local treatments are not appropriate for your situation - You are 18 or older with a Karnofsky Performance Status of at least 50 (able to care for yourself) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your expected survival is less than 6 months - You have uncontrolled brain metastases - You have already had so much radiation that more cannot safely be delivered - You have another active primary cancer - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREradiotherapy

External Beam Radiotherapy - hypofractionated, short radiotherapy regime of 30Gy in 5 fractions (6Gy per fraction) delivered on alternate days over 2 weeks


Locations(1)

The Royal Marsden NHSFT

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06995664


Related Trials